Randomized trial of cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke*

[1]  P. Weinstein,et al.  Protection of the Brain from Ischemia , 1989 .

[2]  J. Marler,et al.  Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.

[3]  M. Fisher,et al.  A Double Blind Trial of Naloxone in the Treatment of Acute Stroke , 1984, Stroke.

[4]  P. Bo,et al.  Kappa-opioid receptor changes and neurophysiological alterations during cerebral ischemia in rabbits. , 1990, Stroke.

[5]  A. Goldstein,et al.  Antinociception and paralysis induced by intrathecal dynorphin A. , 1985, The Journal of pharmacology and experimental therapeutics.

[6]  G. Albers,et al.  Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke , 1995 .

[7]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.

[8]  A. Faden,et al.  Traumatic injury alters opiate receptor binding in rat spinal cord , 1986, Annals of neurology.

[9]  T. Brott,et al.  Improved Reliability of the NIH Stroke Scale Using Video Training , 1994, Stroke.

[10]  T. Beardsley.  Cross reaction. Could AIDS really be an autoimmune disease? , 1991, Scientific American.

[11]  F. Gotoh,et al.  Effects of a Stable Enkephalin Analogue, (D-Met2,Pro5)-Enkephalinamide, and Naloxone on Cortical Blood Flow and Cerebral Blood Volume in Experimental Brain Ischemia in Anesthetized Cats , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  R. Vink,et al.  Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  G. Koch,et al.  The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials , 1991 .

[14]  Y. Namba,et al.  Opiate‐Antagonist Reversal of Neurological Deficits –Experimental and Clinical Studies– , 1986, The Japanese journal of psychiatry and neurology.

[15]  A. Faden.  Neuropeptides and central nervous system injury. Clinical implications. , 1986, Archives of neurology.

[16]  A. Faden,et al.  Increased dynorphin immunoreactivity in spinal cord after traumatic injury , 1985, Regulatory Peptides.

[17]  A. Faden,et al.  Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. , 1990, Archives of neurology.

[18]  H. Shimizu,et al.  Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia , 1993, Brain Research.

[19]  J. Fishman,et al.  Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists. , 1975, Journal of medicinal chemistry.

[20]  J. Olney.  Excitotoxins: An Overview , 1983 .

[21]  B. Weissman,et al.  Binding of a new opiate antagonist, nalmefene, to rat brain membranes. , 1985, Methods and findings in experimental and clinical pharmacology.

[22]  J. Olney,et al.  Glutamate and the pathophysiology of hypoxic–ischemic brain damage , 1986, Annals of neurology.

[23]  V. Moretti,et al.  DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF NALOXONE ON MOTOR DEFICITS IN ACUTE CEREBROVASCULAR DISEASE , 1984, The Lancet.

[24]  J. Grotta,et al.  Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.

[25]  H. Miller,et al.  Multiple sclerosis. A trial of treatment with tolbutamide. , 1961, Lancet.

[26]  P. Weinstein,et al.  Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[27]  M. Lavyne,et al.  Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. , 1986, Journal of neurosurgery.